Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report

Variant acute promyelocytic leukemia (APL) showed quite different aspects, and the current treatments remained challenged at present. Venetoclax, a selective inhibitor of B-cell lymphoma 2 (BCL-2), is a small molecule that has been studied in several hematologic malignancies as both monotherapy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Baoquan, Wang, Xin, Kong, Xin, Wang, Man, Yao, Li, Shen, Hongjie, Zhang, Jian, Qiu, Huiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858936/
https://www.ncbi.nlm.nih.gov/pubmed/35198449
http://dx.doi.org/10.3389/fonc.2022.828852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858936/
https://www.ncbi.nlm.nih.gov/pubmed/35198449
http://dx.doi.org/10.3389/fonc.2022.828852

Ejemplares similares